CClinicalTrials.gg
Status unknownNCT05381168Updated May 19, 2022

Calcium From Fish Bone in Volunteers With Osteopenia

An interventional study of Calcium from fish bone and Calcium carbonate in Osteopenia, sponsored by Chulalongkorn University. Status unknown. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by Chulalongkorn University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Sex
All
01

Study summary

The aims of this study are to explore efficacy and safety of calcium from fish bone in volunteers with osteopenia. The volunteers are divided into 2 groups which are calcium from fish bone treatment group and calcium carbonate treatment group. Both groups received the calciums everyday for 6 months. Bone mineral density, blood examination, physical examination, adverse events, and satisfaction are evaluated before and after treatment.

Read the detailed description

The aims of this study are to explore efficacy and safety of calcium from fish bone in volunteers with osteopenia. The volunteers are divided into 2 groups which are calcium from fish bone treatment group and calcium carbonate treatment group. Both groups received the calciums everyday for 6 months. Bone mineral density is analyzed before and after treatment. Osteocalcin, total procollagen type-1 N-terminal propeptide (P1NP), beta-crosslaps, parathyroid hormone (PTH), calcium, phosphate level, vitamin D level (Serum 25(OH)D), albumin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), creatinine (Cr), blood urea nitrogen (BUN), and complete blood count (CBC) are assessed before and after taking for 3 and 6 months. Physical performance and food diary are also tested and records. Moreover, adverse effects including skin allergy, gastrointestinal abnormality, respiratory abnormality are evaluated. Satisfaction is asked after treatment.

02

Conditions studied

  • Osteopenia

Keywords

  • osteopenia
  • calcium
  • fish bone
  • efficacy
  • safety
03

In context

Bone Diseases, Metabolic

470 studies on the registry are indexed under Bone Diseases, Metabolic; 71 are open to participants now.

This study's planned enrollment of 48 is below the median of 60 across 359 interventional studies indexed under Bone Diseases, Metabolic.

Browse Bone Diseases, Metabolic studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 313 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male age more than 70 years or female age more than 65 years or all age volunteers that have at least 1 risk factors which are menopause before 45 years, menopause with the height reduction (more than 4 cm), body mass index less than 20 kg/mm2, bone fracture history, taking some medicine that has an effect on bone density reduction, have disease that has an effect on bone density reduction, Father and mother have bone fracture history, fracture risk assessment tool (FRAX) in intermediate risk, osteoporosis self-assessment tool for asian (OSTA) score, khon kaen osteoporosis study (KKOS) score in intermediate risk or higher intermediate risk
  • Bone mineral density between -1 to -2.5
  • No osteosclerosis
  • Can read and write
  • Willing to be volunteer

Exclusion criteria

Exclusion Criteria:

  • Allergic to calcium, magnesium, phosphorus, zinc, collagen, and osteocalcin
  • Taking calcium or vitamin D with in 14 days before the study start
  • Taking osteosclerosis' medicine
  • Have uncontrolled diseases
  • Pregnancy and lactation
  • Participating in other study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Calcium from fish bone

    The volunteer will receive calcium from fish bone 4 capsules per day for 6 months.

    Dietary Supplement: Calcium from fish bone

  • Active comparator
    Calcium carbonate

    The volunteer will receive calcium carbonate 2 tablets per day for 6 months.

    Dietary Supplement: Calcium carbonate

Interventions

  • Dietary supplementCalcium from fish bone

    Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.

  • Dietary supplementCalcium carbonate

    Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.

06

What researchers measure

Primary outcomes

  1. Bone mineral density score

    Bone mineral density score is measured using dual energy x-ray absorptiometry scanner (DEXA scanner). It shows in term of T-score. The outcomes are compared bone mineral density score of calcium from fish bone group to calcium carbonate group.

    Time frame: 6 months

Secondary outcomes

  1. Osteocalcin level

    Changing of osteocalcin level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  2. Total procollagen type-1 N-terminal propeptide (P1NP) level

    Changing of P1NP level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  3. Beta-crosslaps level

    Changing of beta-crosslaps level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  4. Parathyroid hormone (PTH) level

    Changing of PTH level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  5. Blood calcium level

    Changing of blood calcium level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  6. Blood phosphate level

    Changing of blood phosphate level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  7. Vitamin D level

    Changing of vitamin D level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  8. Liver function level

    Changing of liver function level (aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP)) of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  9. Creatinine level

    Changing of creatinine (Cr) level of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  10. Blood urea nitrogen level

    Changing of blood urea nitrogen (BUN) of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  11. Pain score

    Changing of pain score using visual analogue scale (0 painless to 10 very pain) of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  12. Short physical performance battery score

    Changing of short physical performance battery score (0 weak to 12 very strong)of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  13. Grip strength

    Changing of grip strength (kilogram) of calcium from fish bone group compared to calcium carbonate group.

    Time frame: 6 months

  14. Skin allergic reactions

    The outcome measurements of skin allergic reactions are appearance (have or no have) of rash, edema, bullae, pain, and itching.

    Time frame: 6 months

  15. Respiratory tract abnormality

    The outcome measurements of respiratory tract abnormality are appearance (have or no have) of shortness of breath and asthma.

    Time frame: 6 months

  16. Gastrointestinal tract abnormality

    The outcome measurements of gastrointestinal tract abnormality are appearance (have or no have) of nausea, vomiting, flatulence, constipation, and diarrhea.

    Time frame: 6 months

  17. Satisfaction level

    Satisfaction score (0 unsatisfied to 10 very satisfied)

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05381168
Lead sponsor
Chulalongkorn University
Responsible party
Pornanong Aramwit, Pharm.D., Ph.D (Professor, Chulalongkorn University) — Principal investigator
First posted
May 19, 2022
Start date
May 20, 2022 (estimated)
Primary completion
Nov 30, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
May 19, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion